Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with companies executive. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.

Recently Added News

6/17/2021
Press Release
Phoenix, Knoxville, Kansas City Stand Out for Retinal Treatment Opportunity in the US
Phoenix, Knoxville, Kansas City Stand Out for Retinal Treatment Opportunity in the US

The Phoenix metro area has the highest number of vitrectomies per provider in the US, while Knoxville, Tennessee, stands out for above average annual intravitreal injection volumes per provider. Ka...

6/18/2021
BreakingClinical TrialGene TherapyRetina
Biogen’s Choroideremia Candidate Fails to Meet Phase III Endpoints; News Follows Disappointing XLRP Trial Results
Biogen’s Choroideremia Candidate Fails to Meet Phase III Endpoints; News Follows Disappointing XLRP Trial Results

Biogen announced June 14 that its gene therapy candidate for choroideremia, timrepigene emparvovec (BIIB111/AAV2-REP1), had failed to meet primary and key secondary endpoints in the Phase III STAR ...

6/18/2021
BreakingCataractIOLSurgical
J&J Vision Launches TECNIS Eyhance Toric II in Europe
J&J Vision Launches TECNIS Eyhance Toric II in Europe

Johnson & Johnson Vision’s surgical unit announced June 8 that it had begun the European launch of its TECNIS Eyhance Toric II IOL, with the TECNIS Simplicity Delivery System. The company describes...

6/18/2021
BreakingClinical TrialGene TherapyRetina
Nanoscope Says its Optogenetic Gene Therapy Restores Clinically Meaningful Vision in 11 RP Patients
Nanoscope Says its Optogenetic Gene Therapy Restores Clinically Meaningful Vision in 11 RP Patients

Nanoscope Therapeutics reported June 3 that vision improvements for all evaluated advanced retinitis pigmentosa (RP) patients persisted through one year following a single intravitreal injection in...

6/18/2021
BreakingClinical TrialGlaucomaPharma
Glaukos Completes Enrollment in US Phase III Trials for iDose Travoprost Implant
Glaukos Completes Enrollment in US Phase III Trials for iDose Travoprost Implant

Glaukos announced June 10 that it had completed enrollment and randomization in its US FDA Phase III clinical trials for the iDose TR sustained-release travoprost implant. Two double-masked trials ...

6/18/2021
BreakingDeviceGlaucomaRegulation
PreserFlo MicroShunt for Glaucoma Gains Approval in Australia
PreserFlo MicroShunt for Glaucoma Gains Approval in Australia

Glaukos announced June 8 that Australia’s Therapeutic Goods Administration (TGA) had granted regulatory approval for the PreserFlo MicroShunt. The PreserFlo is an ab externo drainage system that re...

6/18/2021
BreakingFundingPharmaRetina
Molecular Partners Launches $63.8 Million IPO to Advance DARPin Technology
Molecular Partners Launches $63.8 Million IPO to Advance DARPin Technology

Swiss company Molecular Partners announced June 16 the pricing of a $63.8 million initial public offering in the US of 3 million American Depositary Shares at a public offering price of $21.25 per ...

6/18/2021
BreakingDealsPharma
Oyster Point, APT to Collaborate on Ophthalmic Treatments for Drug-Resistant Infections
Oyster Point, APT to Collaborate on Ophthalmic Treatments for Drug-Resistant Infections

Oyster Point Pharma, of Princeton, New Jersey, announced June 10 that it had formed a research collaboration with Adaptive Phage Therapeutics (APT) to leverage APT’s PhageBank technology for the de...

6/11/2021
Corneal
EyeYon Medical’s EndoArt Implant Gains CE Marking for Chronic Corneal Edema
EyeYon Medical’s EndoArt Implant Gains CE Marking for Chronic Corneal Edema

Israeli company EyeYon Medical reported June 8 that it had gained CE marking for its EndoArt implant, a synthetic implant attached to the posterior corneal surface to treat chronic corneal edema se...

6/11/2021
Corneal
Oyster Point Expands Pipeline with Tear Film Gene Therapy Candidate
Oyster Point Expands Pipeline with Tear Film Gene Therapy Candidate

Oyster Point Pharma reported June 3 that it was expanding its pipeline with the introduction of a gene therapy candidate targeting the tear film in patients with neurotrophic keratopathy. The Princ...

6/11/2021
CataractPharma
Salvat’s Candidate for Post-Cataract Inflammation and Pain Completes Phase III Trials in US
Salvat’s Candidate for Post-Cataract Inflammation and Pain Completes Phase III Trials in US

Spanish company Salvat announced June 2 that it had completed Phase III clinical trials in the US for its drug candidate for the treatment of ocular inflammation and pain after cataract surgery. Th...

6/11/2021
CataractDevice
VSY Launches Enova Hydrophobic Acrylic IOL
VSY Launches Enova Hydrophobic Acrylic IOL

German company VSY Biotechnology announced June 3 the launch of the Enova intraocular lens (IOL). VSY describes the lens as a 100 percent glistening-free, dry-packed hydrophobic acrylic IOL. The En...

Past News Stories

6/11/2021
DealsDiagnosticTelemedicine
Harrow’s Visionology Licenses SPARCS Contrast Sensitivity Testing Technology
Harrow’s Visionology Licenses SPARCS Contrast Sensitivity Testing Technology

Visionology, a subsidiary of Harrow Health, announced June 3 that it had acquired a worldwide exclusive license from Spaeth/Richman Contrast Sensitivity Center (SPARCS) to make its technology avail...

6/11/2021
DealsDry Eye
Arctic Vision Licenses Olympic’s iTEAR 100 for Greater China, South Korea, and ASEAN Countries
Arctic Vision Licenses Olympic’s iTEAR 100 for Greater China, South Korea, and ASEAN Countries

China-based Arctic Vision reported June 6 that it signed an exclusive licensing agreement with Olympic Ophthalmics to develop and market Olympic’s iTEAR 100 for dry eye disease in Greater China (ma...

6/11/2021
Deals
Pieris Gets $20 Million Up Front in Collaboration with Genentech on Ophthalmic, Respiratory Candidates
Pieris Gets $20 Million Up Front in Collaboration with Genentech on Ophthalmic, Respiratory Candidates

Pieris Pharmaceuticals announced May 25 that it had entered into a collaboration and license agreement with Genentech to develop respiratory and ophthalmology therapies that leverage Pieris’ propri...

6/11/2021
DealsFundingPharma
Ocuphire Prices $15 Million Registered Direct Offering
Ocuphire Prices $15 Million Registered Direct Offering

Ocuphire Pharma announced June 4 that it had entered into a securities purchase agreement with institutional investors for 3 million shares of common stock and warrants to purchase an additional 1....

6/11/2021
Deals
Transine Therapeutics Secures $12.9 Million in Seed Funding to Advance Therapeutic RNA Candidates
Transine Therapeutics Secures $12.9 Million in Seed Funding to Advance Therapeutic RNA Candidates

Transine Therapeutics announced June 2 that it had secured £9.1 million ($12.9 million) in seed funding to advance a novel class of therapeutic RNAs based on its SINEUP platform technology. The Cam...

6/11/2021
Retina
Lineage Reports Additional Cases of Retinal Tissue Restoration in Dry AMD Patients Treated with OpRegen
Lineage Reports Additional Cases of Retinal Tissue Restoration in Dry AMD Patients Treated with OpRegen

Lineage Cell Therapeutics reported June 1 that restoration of retinal tissue was observed in two additional patients enrolled in a Phase I/IIa study of OpRegen retinal pigment epithelium (RPE) cell...

6/11/2021
Corneal
Greg Kunst Appointed CEO of Aurion Biotech
Greg Kunst Appointed CEO of Aurion Biotech

Newly launched Aurion Biotech announced June 8 that industry veteran Greg Kunst would be its chief executive officer. The ophthalmic company is a division of CorneaGen and will be based in Seattle ...

6/11/2021
PharmaRetina
Oxular appoints Friedrich Asmus, MD, as Chief Medical Officer
Oxular appoints Friedrich Asmus, MD, as Chief Medical Officer

Retinal pharmaceutical company Oxular, of Oxford, England, reported June 7 that it had appointed Friedrich Asmus, MD, as chief medical officer (CMO). Asmus is a board-certified neurologist and phar...

6/2/2021
Press Release
Ophthalmic Laser Market Expected to Total $376.4 Million in 2021
Ophthalmic Laser Market Expected to Total $376.4 Million in 2021

Global revenue for ophthalmic lasers—photocoagulation, photodisruption (YAG), and SLT—along with maintenance, accessories, and endoprobes, will total over $376.4 million in 2021 and grow at a compo...

6/4/2021
BreakingClinical TrialPharmaRetina
Novartis Stops Three Phase III Studies of Beovu over Inflammation 
Novartis Stops Three Phase III Studies of Beovu over Inflammation

Novartis announced May 28 that it had terminated three Phase III studies of Beovu in the US due to intraocular inflammation seen in one—the MERLIN study. MERLIN had been using monthly treatment int...

6/4/2021
BreakingRetina
Neurophth, Hopstem Form Partnership to Develop Stem Cell-Derived Therapies for Ocular Diseases
Neurophth, Hopstem Form Partnership to Develop Stem Cell-Derived Therapies for Ocular Diseases

Chinese companies Neurophth Biotechnology and Hopstem Biotechnology announced June 1 that they had formed a strategic partnership aiming to provide human induced pluripotent stem cell (iPSC) therap...

6/4/2021
BreakingDiagnostic
Haag-Streit Accepting Submissions for Third Annual Slit Lamp Imaging Competition
Haag-Streit Accepting Submissions for Third Annual Slit Lamp Imaging Competition

Switzerland-based Haag-Streit Diagnostics has announced its third annual Slit Lamp Imaging Competition. The global competition is open to eye care professionals who want to showcase their imaging s...

Want to Read the Full Article?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more